Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion type Assertion NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_head.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion description "[Here, we report that phosphomimetic mutants of PEDF, which possess significantly increased antiangiogenic activity, are much more efficient than wild-type (WT) PEDF in inhibiting growth and neovascularization in MDA-MB-231 (breast cancer), HCT116 (colon cancer), and U87-MG (glioblastoma) xenograft models.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_provenance.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion evidence source_evidence_literature NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_provenance.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion SIO_000772 20610633 NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_provenance.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion wasDerivedFrom befree-20140225 NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_provenance.
- NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_assertion wasGeneratedBy ECO_0000203 NP396452.RAC7EmGVHR4cuwHCPrWT3mlqSZT6KnnbCyBN_Sf5-i7E8130_provenance.